There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.
Full Title of Study: “Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study”
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: December 2019
- Other: skin biopsy before and after NB-UVB phototherapy
- skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
Arms, Groups and Cohorts
- Experimental: vitiligo patients
- Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
- Active Comparator: Healthy controls
- Tissue levels of human beta-defensin 1 in healthy controls
Clinical Trial Outcome Measures
- Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
- Time Frame: 6 months to 1 year
Participating in This Clinical Trial
- Patients with non-segmental vitiligo.
- Both genders.
- Age more than 18 years old.
- New cases or cases not receiving any treatment for at least 3 months prior to the study.
- Universal or segmental vitiligo.
- Any contraindication to phototherapy treatment.
- History of autoimmune diseases or other systemic diseases.
- Any other skin disease.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Cairo University
- Provider of Information About this Clinical Study
- Principal Investigator: Maha Fathy Elmasry, principal investigator – Cairo University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.